Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics

Brand Names


Belgium: Motens; Czech Republic: Lacipil; Denmark: Lacipil, Midotens, Motens; Estonia: Lacipil; France: Caldine; Germany: Motens; Greece: Lacipil, Lacitens, Motens; Hungary: Lacipil; Italy: Aponil-Glaxo Allen, Lacipil, Lacirex, Ladip, Viapres; Latvia: Lacipil; Lithuania: Lacipil; Luxembourg: Motens; Netherlands: Motens; Poland: Cinep, Lacipil; Portugal: Lacidipina, Lacipil, Tens; Romania: Lacipil; Slovakia: Lacipil; Slovenia: Lacipil; Spain: Lacimen, Lacipil, Motens; UK: Motens.

Latin America

Brazil: Lacipil, Midotens; Mexico: Lacipil, Midotens.

Drug combinations


Lacidipine: C~26~H~33~NO~6~. Mw: 455.54. (1) 3,5-Pyridinedicarboxylic acid, 4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-, diethyl ester, (E)-; (2) 4-[o-(E)-2-Carboxyvinyl]-phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, 4-tert-butyl diethyl ester. CAS-103890-78-4 (1989).

Pharmacologic Category

Cardiovascular Drugs; Calcium-Channel Blocking Agents; Dihydropyridines. (ATC-Code: C08CA09).

Mechanism of action

A specific and potent calcium antagonist with predominant selectivity for calcium channels in vascular smooth muscle. Its main action is to dilate peripheral arterioles, reducing peripheral vascular resistance and lowering blood pressure.

Therapeutic use

Indicated for treatment of hypertension either alone or in combination with other antihypertensive agents, including β-adrenoceptor antagonists, diuretics, and ACEIs.

Pregnancy and lactiation implications

Should not be used during pregnancy or lactation.

Unlabeled use


Contraindicated in known hypersensitivity to any ingredient of the preparation. Should only be used with great care in previous allergic reaction to another dihydropyridine; theoretical risk of cross-reactivity. As with other calcium antagonists, lacidipine should be discontinued in patients who develop cardiogenic shock and unstable angina. In addition, dihydropyridines shown to reduce coronary arterial blood-flow in aortic stenosis; in such patients lacidipine is contraindicated. Should not be used during or within one month of MI.

Warnings and precautions

Theoretical potential for a calcium antagonist to affect activity of SA and AV nodes should be noted, and care should be taken in pre-existing abnormalities. Use with caution in congenital or documented acquired QT prolongation, in patients treated concomitantly with medications known to prolong QT interval such as class I and III antiarrhythmics, tricyclic antidepressants, certain antipsychotics, antibiotics, antihistaminic agents. Use with caution in poor cardiac reserve, and in hepatic impairment (antihypertensive effect may be increased). Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this drug.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart